Global Information
회사소개 | 문의 | 비교리스트

세계의 당뇨병성 신경병증 치료제 시장(2019-2023년)

Global Diabetic Neuropathy Drugs Market 2019-2023

리서치사 TechNavio (Infiniti Research Ltd.)
발행일 2019년 03월 상품 코드 823147
페이지 정보 영문 135 Pages
가격
US $ 2,500 ₩ 3,122,000 PDF by E-mail (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 3,000 ₩ 3,746,000 PDF by E-mail (5-user License) help
동일 사업장 내 5명까지 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,995,000 PDF by E-mail (Enterprise License) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 6,244,000 PDF by E-mail (Global License) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다. 또한 해당 라이선스는 보고서 컨텐츠의 15% 이내로 외부용 문서에 인용 게재가 허용됩니다(예:프레스릴리스, 마케팅 자료, 백서 등).


세계의 당뇨병성 신경병증 치료제 시장(2019-2023년) Global Diabetic Neuropathy Drugs Market 2019-2023
발행일 : 2019년 03월 페이지 정보 : 영문 135 Pages

당뇨병성 신경병증에 대한 인식 향상은 향후 수년간 당뇨병성 신경병증 치료제(Diabetic Neuropathy Drugs) 시장의 성장에 기여할 가능성이 높은 유력한 요인 중 하나입니다. 신흥 국가 및 선진국의 당뇨병 지도자 교육과 훈련을 목적으로 구입자간 계발 프로그램이 몇가지 개시되었습니다. 다양한 캠페인에 의해 당뇨병 전단계에 관련된 위험인자에 대해 알기 위한 온라인 테스트를 받는 것이 장려되고 있으며, 예측 기간 중 당뇨병성 신경병증 치료제 시장의 성장을 촉진하고 있습니다. Technavio의 애널리스트는 세계의 당뇨병성 신경병증 치료제 시장이 2023년까지 약 6%의 CAGR로 성장할 것으로 예측했습니다.

세계의 당뇨병성 신경병증 치료제 시장에 대해 조사분석했으며, 시장 규모와 성장률, 시장 동향, 시장 성장 촉진요인·과제, 시장 기회 검증 및 주요 벤더 등에 관한 정보를 정리하여 전해드립니다.

제1장 개요

제2장 리포트의 범위

  • 서론 1
  • 서론 2
  • 달러의 통화 환산율

제3장 시장 상황

  • 시장 에코시스템
  • 시장의 특징
  • 시장 세분화 분석

제4장 시장 규모

  • 시장의 정의
  • 시장 규모(2018년)
  • 시장 규모 및 예측(2018-2023년)

제5장 Five Forces 분석

  • 바이어의 교섭력
  • 공급업체의 교섭력
  • 신규 진출의 위협
  • 대체품의 위협
  • 경쟁 상대의 위협
  • 시장 현황

제6장 고객 상황

제7장 지역별 상황

  • 지역별 세분화
  • 지역별 비교 : 시장 규모 및 예측(2018-2023년)
  • 북미
  • 유럽
  • 아시아
  • 기타 지역
  • 주요 국가
  • 시장 기회

제8장 시장 세분화 : 작용기서별

  • 시장 세분화 : 작용기서별
  • 작용기서별 비교 : 시장 규모 및 예측(2018-2023년)
  • 칼슘 채널 알파-2-델타 리간드
  • SNRI와 TCA
  • 기타
  • 시장 기회 : 작용기서별

제9장 성장요인과 과제

  • 시장 성장요인
  • 시장이 해결해야 할 과제

제10장 시장 동향

  • 시장 동향

제11장 벤더 구도

  • 개요
  • 창조적 파괴 상황
  • 경쟁 시나리오

제12장 벤더 분석

  • 대상 벤더
  • 벤더 분류
  • 벤더의 시장 포지셔닝
  • DAIICHI SANKYO COMPANY, LIMITED
  • Eli Lilly and Company
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Pfizer Inc.

제13장 부록

  • 조사 방법
  • 약어 리스트
KSA 19.04.19

About this market

The rising awareness about diabetic neuropathy is one of the prominent factors likely to contribute to the diabetic neuropathy drugs market growth in the forthcoming years. Several awareness programs are being launched among the consumers with an aim to educate and train diabetes educators in the emerging and advanced economies. Different campaigns are encouraging people to take an online test for knowing about the risk factors associated with prediabetes, in turn, driving the diabetic neuropathy drugs market growth during the forecast period. Technavio's analysts have predicted that the diabetic neuropathy drugs market will register a CAGR of about 6% by 2023.

Market Overview

New drug approvals and strong drug pipeline

One of the growth drivers of the global diabetic neuropathy drugs market is new drug approvals and strong drug pipeline. With the rising prevalence of diabetic neuropathy, several market players are focusing on the development of disease-modifying drugs to treat the disease.

Side-effects of major drugs

One of the challenges in the growth of the global diabetic neuropathy drugs market is the side-effects of major drugs. Side-effects associated with approved drugs such as pregabalin (LYRICA) and gabapentin (NEURONTIN) can lead to low patient compliance, thereby hindering the growth of the market.

For the detailed list of factors that will drive and challenge the growth of the diabetic neuropathy drugs market during 019-2023, view our report.

Competitive Landscape

The market appears to be moderately fragmented with the presence of several market players. Vendors in the market are focusing on the development of novel biologics to treat diabetic neuropathy. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: CUSTOMER LANDSCAPE

PART 07: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 08: MARKET SEGMENTATION BY MECHANISM OF ACTION

  • Market segmentation by mechanism of action
  • Comparison by mechanism of action
  • Calcium channel alpha-2-delta ligand - Market size and forecast 2018-2023
  • SNRIs and TCAs - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by mechanism of action

PART 09: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 10: MARKET TRENDS

  • Market trends

PART 11: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 12: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • DAIICHI SANKYO COMPANY, LIMITED
  • Eli Lilly and Company
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Pfizer Inc.

PART 13: APPENDIX

  • Research methodology
  • List of abbreviations

List of Exhibits

  • Exhibit 01: Years in consideration
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Customer landscape
  • Exhibit 19: Market share by geography 2018-2023 (%)
  • Exhibit 20: Geographic comparison
  • Exhibit 21: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 24: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 25: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 26: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 27: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 28: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 29: Key leading countries
  • Exhibit 30: Market opportunity
  • Exhibit 31: Mechanism of action - Market share 2018-2023 (%)
  • Exhibit 32: Comparison by mechanism of action
  • Exhibit 33: Calcium channel alpha-2-delta ligand - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 34: Calcium channel alpha-2-delta ligand - Year-over-year growth 2019-2023 (%)
  • Exhibit 35: SNRIs and TCAs - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 36: SNRIs and TCAs - Year-over-year growth 2019-2023 (%)
  • Exhibit 37: Others - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 38: Others - Year-over-year growth 2019-2023 (%)
  • Exhibit 39: Market opportunity by mechanism of action
  • Exhibit 40: Decision framework
  • Exhibit 41: Pipeline drugs for diabetic neuropathy
  • Exhibit 42: Impact of drivers and challenges
  • Exhibit 43: Biologics under development
  • Exhibit 44: Vendor landscape
  • Exhibit 45: Landscape disruption
  • Exhibit 46: Vendors covered
  • Exhibit 47: Vendor_analysis1
  • Exhibit 48: Vendor classification
  • Exhibit 49: Market positioning of vendors
  • Exhibit 50: DAIICHI SANKYO COMPANY, LIMITED - Vendor overview
  • Exhibit 51: DAIICHI SANKYO COMPANY, LIMITED - Business segments
  • Exhibit 52: DAIICHI SANKYO COMPANY, LIMITED - Organizational developments
  • Exhibit 53: DAIICHI SANKYO COMPANY, LIMITED - Geographic focus
  • Exhibit 54: DAIICHI SANKYO COMPANY, LIMITED - Segment focus
  • Exhibit 55: DAIICHI SANKYO COMPANY, LIMITED - Key offerings
  • Exhibit 56: Eli Lilly and Company - Vendor overview
  • Exhibit 57: Eli Lilly and Company - Business segments
  • Exhibit 58: Eli Lilly and Company - Organizational developments
  • Exhibit 59: Eli Lilly and Company - Geographic focus
  • Exhibit 60: Eli Lilly and Company - Segment focus
  • Exhibit 61: Eli Lilly and Company - Key offerings
  • Exhibit 62: Johnson & Johnson Services, Inc. - Vendor overview
  • Exhibit 63: Johnson & Johnson Services, Inc. - Business segments
  • Exhibit 64: Johnson & Johnson Services, Inc. - Organizational developments
  • Exhibit 65: Johnson & Johnson Services, Inc. - Geographic focus
  • Exhibit 66: Johnson & Johnson Services, Inc. - Segment focus
  • Exhibit 67: Johnson & Johnson Services, Inc. - Key offerings
  • Exhibit 68: Novartis AG - Vendor overview
  • Exhibit 69: Novartis AG - Business segments
  • Exhibit 70: Novartis AG - Organizational developments
  • Exhibit 71: Novartis AG - Geographic focus
  • Exhibit 72: Novartis AG - Segment focus
  • Exhibit 73: Novartis AG - Key offerings
  • Exhibit 74: Pfizer Inc. - Vendor overview
  • Exhibit 75: Pfizer Inc. - Business segments
  • Exhibit 76: Pfizer Inc. - Organizational developments
  • Exhibit 77: Pfizer Inc. - Geographic focus
  • Exhibit 78: Pfizer Inc. - Segment focus
  • Exhibit 79: Pfizer Inc. - Key offerings
  • Exhibit 80: Validation techniques employed for market sizing
  • Exhibit 81: List of abbreviations
Back to Top
전화 문의
F A Q